KALA BIO, Inc. (KALA) Stock Profile — Insider Trades & Financials

Net Income-$7.6M

EPS$-4.17

Market Cap$1.5M

Price Performance

Historical data including institutional events

Loading price data...

Company Profile

Avi Minkowitz

CEO & Executive Director

KALA BIO, Inc. a clinical-stage biopharmaceutical company, engages in the research, development, and commercialization of therapies for rare and severe eye diseases. The companyâs lead product candidates include KPI-012, which is in Phase 2b clinical trial for the treatment of persistent corneal epithelial defects; and limbal stem cell deficiency and other rare corneal diseases. Its preclinical development product consists of KPI-014 for the treatment of rare inherited retinal diseases. The company was formerly known as Kala Pharmaceuticals, Inc. and changed its name to KALA BIO, Inc. in August 2023. KALA BIO, Inc. was incorporated in 2009 and is headquartered in Arlington, Massachusetts.

Founded: 2009
Employees: 38
Headquarters: Arlington, Massachusetts, United States

⚡

Core Efficiency

ROE?

87.29%

ROA?

-30.23%

D/E Ratio?

-3.89

📊

Profitability Ratios

Current Ratio?

0.75

Loading comparison...

Earnings Calendar

Filing history and next expected filing date

Nov 19, 2025

10-QQ3 20251d after period end

Aug 8, 2025

10-QQ2 20251d after period end

May 14, 2025

10-QQ1 20251d after period end

Mar 31, 2025

10-KQ4 20243d after period end

Nov 12, 2024

10-QQ3 20241d after period end

Aug 6, 2024

10-QQ2 20241d after period end

May 14, 2024

10-QQ1 20241d after period end

Mar 29, 2024

10-KQ4 20231d after period end

Loading company sections...

KALA BIO, Inc.

Price Performance

Company Profile

Core Efficiency

Profitability Ratios

Earnings Calendar

Core Efficiency

Profitability Ratios

Earnings Calendar

Data Freshness